New data presented at the recent ESMO (European Society for Medical Oncology) 2020 conference discusses 3 trials, CheckMate, Attraction 4, and Keynote 590 supporting the use of immunotherapy for gastric and oesophageal cancer patients with poor survival prognoses. As indicated in the ESMO press release "immune checkpoint inhibitors are not yet approved for early therapy in Western countries." The trials thus provide evidence on the use of different immune checkpoint inhibitors as first-line therapy regimens.
To read more about these trials, click here.
No comments:
Post a Comment